scholarly journals Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion

2021 ◽  
Author(s):  
Vanessa Boudewyns ◽  
Amie C. O'Donoghue ◽  
Ryan S. Paquin ◽  
Kathryn J. Aikin ◽  
Kate Ferriola‐Bruckenstein ◽  
...  
Keyword(s):  
Prescription Drug ◽  
Clinical Utility ◽  
Drug Promotion

Patterns of Prescription Drug Use: The Role of Promotion

1973 ◽  
Vol 3 (4) ◽  
pp. 389-402 ◽  
Author(s):  
C. Joseph Stetler
Keyword(s):  
Drug Abuse ◽  
Prescription Drug ◽  
Prescribing Patterns ◽  
Pharmaceutical Manufacturers ◽  
Prescription Drug Use ◽  
Drug Promotion ◽  
Promotional Efforts ◽  
The Subject ◽  
Physician Prescribing

Promotional efforts directed to the health professions by pharmaceutical manufacturers, and their alleged association with excessive prescribing and drug abuse are the subject of this paper. The paper contends that claims to the effect that legitimate drug prescribing patterns and promotional efforts merely mirror—or even may cause—drug abuse are not factually supported. Assertions to the effect that physicians rely primarily on advertising in making prescribing decisions are not borne out by studies of the various factors which bear upon those decisions, the paper points out. It describes the extent of prescription drug promotion, and utilization and notes that physician prescribing of psychoactive drugs has lagged behind overall prescription growth trends, in contrast to the accelerating misuse and abuse of this class of medications in the community at large.

scholarly journals Demand Effects of Recent Changes in Prescription Drug Promotion

2003 ◽  
Vol 6 (1) ◽  
Author(s):  
Meredith B. Rosenthal ◽  
Ernst R. Berndt ◽  
Julie M. Donohue ◽  
Arnold M. Epstein ◽  
Richard G. Frank
Keyword(s):  
Prescription Drug ◽  
Drug Market ◽  
Drug Spending ◽  
Direct To Consumer ◽  
On Demand ◽  
Therapeutic Class ◽  
Drug Promotion ◽  
Prescription Drug Spending ◽  
Direct To Consumer Advertising ◽  
Prescription Drug Market

The release of clarified Food and Drug Administration (FDA) guidelines and independent changes in consumer behavior provide an opportunity to study the effects of direct-to-consumer advertising (DTCA) in the prescription drug market alongside the effects of various physician-oriented promotions. We examine the effects of DTCA and detailing for brands in five therapeutic classes of drugs, using monthly aggregate U.S. data from August 1996 through December 1999. In terms of impact of DTCA on demand, we provide evidence on two issues: (1) do increases in DTCA increase the market size of an entire therapeutic class? and (2) does DTCA increase within-class market share of advertised drugs? Our findings suggest that, for these classes of drugs, DTCA has been effective primarily through increasing the size of the entire class. Overall, we estimate that 13 to 22 percent of the recent growth in prescription drug spending is attributable to the effects of DTCA.

scholarly journals Physicians' Understanding of Clinical Trial Data in Professional Prescription Drug Promotion

2018 ◽  
Vol 31 (4) ◽  
pp. 645-649 ◽  
Author(s):  
Caitlin K. Moynihan ◽  
Panne A. Burke ◽  
Sarah A. Evans ◽  
Amie C. O'Donoghue ◽  
Helen W. Sullivan
Keyword(s):  
Clinical Trial ◽  
Prescription Drug ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Drug Promotion
Sign in / Sign up

Export Citation Format

Share Document